Bio-De-Sys Inc. Files 2024 Annual Report
Ticker: BDSX · Form: 10-K · Filed: Mar 3, 2025 · CIK: 1439725
| Field | Detail |
|---|---|
| Company | Biodesix Inc (BDSX) |
| Form Type | 10-K |
| Filed Date | Mar 3, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, annual-report, financials
TL;DR
Bio-De-Sys 2024 10-K is in. Check financials and future outlook.
AI Summary
Bio-De-Sys Inc. filed its 10-K for the fiscal year ending December 31, 2024, reporting on its financial performance and business operations. The company, incorporated in Delaware, is based in Louisville, Colorado. Key financial data and operational details for the period are disclosed in this comprehensive annual report.
Why It Matters
This filing provides investors and stakeholders with a detailed overview of Bio-De-Sys Inc.'s financial health, strategic direction, and potential risks for the fiscal year 2024, influencing investment decisions.
Risk Assessment
Risk Level: medium — The filing contains numerous financial instruments, contingent considerations, and debt facilities, indicating potential financial complexities and risks.
Key Numbers
- P3Y — Five Years (Indicates a period of five years for financial reporting or analysis.)
- P7Y — Seven Years (Indicates a period of seven years, potentially for long-term financial commitments or reporting.)
Key Players & Entities
- BIODESIX INC (company) — Filer
- 2024-12-31 (date) — Fiscal Year End
- 2025-03-03 (date) — Filing Date
- Louisville, CO (location) — Business Address
- Integrated Diagnostics Inc (company) — Mentioned in relation to contingent consideration
- AVEO Oncology (company) — Mentioned in relation to NSCLC POCT Trial
FAQ
What was the total revenue for Bio-De-Sys Inc. for the fiscal year ending December 31, 2024?
The provided text does not explicitly state the total revenue for the fiscal year ending December 31, 2024. It is a summary of the filing's metadata.
What is the company's primary business as indicated by its SIC code?
The company's Standard Industrial Classification (SIC) code is 8071, which corresponds to SERVICES-MEDICAL LABORATORIES.
When was the Third Amendment to the APA Agreement dated?
The Third Amendment to the APA Agreement is dated between April 1, 2022, and April 30, 2022.
What is the filing number for this 10-K report?
The SEC File Number for this 10-K report is 001-39659.
Does the filing mention any specific trials or programs?
Yes, the filing mentions the 'NSCLC POCT Trial' in relation to AVEO Oncology.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 3, 2025 regarding BIODESIX INC (BDSX).